(KYMR) Kymera Therapeutics - Ratings and Ratios
IRAK4 Program,STAT6 Program,TYK2 Program
KYMR EPS (Earnings per Share)
KYMR Revenue
Description: KYMR Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that leverages the bodys natural protein degradation system to develop small molecule therapeutics targeting disease-causing proteins. The companys pipeline includes IRAK4, a program in Phase II clinical trials for treating immunology-inflammation diseases such as hidradenitis suppurativa and atopic dermatitis.
The companys focus on protein degradation technology has led to the development of multiple programs, including STAT6 for type 2 inflammation in allergic and atopic diseases, and TYK2 for autoimmune and inflammatory diseases. Kymera has also established a strategic alliance with Sanofi S.A. for the development of IRAK4-targeting drug candidates outside of oncology and immuno-oncology fields.
From a financial perspective, Kymera Therapeutics has a market capitalization of approximately $3.07 billion. Given its stage of development, the company does not have a positive P/E ratio. Key performance indicators (KPIs) to watch include the progression of its clinical trials, particularly the IRAK4 program, and the expansion of its partnerships and collaborations. Other relevant metrics may include cash burn rate, research and development expenses as a percentage of revenue, and the number of upcoming milestones.
To further evaluate Kymeras potential, investors may also consider the competitive landscape of the biopharmaceutical industry, particularly in the protein degradation space. The companys ability to successfully navigate clinical trials and bring its therapeutics to market will be crucial to its long-term success. Monitoring news and updates from the company, as well as announcements from its partner Sanofi S.A., will be essential in assessing the companys progress.
KYMR Stock Overview
| Market Cap in USD | 3,360m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-08-21 |
KYMR Stock Ratings
| Growth Rating | 14.3% |
| Fundamental | 26.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -18.0% |
| Analyst Rating | 4.55 of 5 |
KYMR Dividends
Currently no dividends paidKYMR Growth Ratios
| Growth Correlation 3m | -62.3% |
| Growth Correlation 12m | -26.7% |
| Growth Correlation 5y | -24.4% |
| CAGR 5y | 22.18% |
| CAGR/Max DD 3y | 0.31 |
| CAGR/Mean DD 3y | 1.14 |
| Sharpe Ratio 12m | 0.17 |
| Alpha | -20.16 |
| Beta | 0.948 |
| Volatility | 54.70% |
| Current Volume | 579.4k |
| Average Volume 20d | 592.4k |
| Stop Loss | 44.2 (-5.9%) |
| Signal | 0.85 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-275.4m TTM) > 0 and > 6% of Revenue (6% = 2.68m TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA -1.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1433 % (prev 523.2%; Δ 910.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.22 (>3.0%) and CFO -251.0m > Net Income -275.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (80.4m) change vs 12m ago 10.12% (target <= -2.0% for YES) |
| Gross Margin 81.87% (prev 94.17%; Δ -12.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.57% (prev 10.72%; Δ -6.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -954.1 (EBITDA TTM -277.2m / Interest Expense TTM 299.0k) >= 6 (WARN >= 3) |
Altman Z'' -6.73
| (A) 0.57 = (Total Current Assets 728.3m - Total Current Liabilities 87.5m) / Total Assets 1.13b |
| (B) -0.79 = Retained Earnings (Balance) -896.8m / Total Assets 1.13b |
| (C) -0.29 = EBIT TTM -285.3m / Avg Total Assets 978.5m |
| (D) -5.62 = Book Value of Equity -896.5m / Total Liabilities 159.6m |
| Total Rating: -6.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.16
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -7.46% = -3.73 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda -0.31 = -2.50 |
| 6. ROIC - WACC -42.01% = -12.50 |
| 7. RoE -31.60% = -2.50 |
| 8. Rev. Trend -1.35% = -0.07 |
| 9. Rev. CAGR 6.90% = 0.86 |
| 10. EPS Trend -36.00% = -0.90 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of KYMR shares?
Over the past week, the price has changed by +8.62%, over one month by +13.09%, over three months by +0.32% and over the past year by -3.07%.
Is Kymera Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KYMR is around 39.99 USD . This means that KYMR is currently overvalued and has a potential downside of -14.9%.
Is KYMR a buy, sell or hold?
- Strong Buy: 14
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KYMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.2 | 32.4% |
| Analysts Target Price | 62.2 | 32.4% |
| ValueRay Target Price | 44.9 | -4.5% |
Last update: 2025-09-15 04:39
KYMR Fundamental Data Overview
CCE Cash And Equivalents = 665.4m USD (Cash And Short Term Investments, last quarter)
P/S = 75.142
P/B = 3.4583
Beta = 2.177
Revenue TTM = 44.7m USD
EBIT TTM = -285.3m USD
EBITDA TTM = -277.2m USD
Long Term Debt = 72.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 85.7m USD (Calculated: Short Term 13.7m + Long Term 72.0m)
Net Debt = -250.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.78b USD (3.36b + Debt 85.7m - CCE 665.4m)
Interest Coverage Ratio = -954.1 (Ebit TTM -285.3m / Interest Expense TTM 299.0k)
FCF Yield = -7.46% (FCF TTM -207.3m / Enterprise Value 2.78b)
FCF Margin = -463.7% (FCF TTM -207.3m / Revenue TTM 44.7m)
Net Margin = -616.0% (Net Income TTM -275.4m / Revenue TTM 44.7m)
Gross Margin = 81.87% ((Revenue TTM 44.7m - Cost of Revenue TTM 8.11m) / Revenue TTM)
Tobins Q-Ratio = -3.10 (set to none) (Enterprise Value 2.78b / Book Value Of Equity -896.5m)
Interest Expense / Debt = 0.13% (Interest Expense 108.0k / Debt 85.7m)
Taxrate = 21.0% (US default)
NOPAT = -285.3m (EBIT -285.3m, no tax applied on loss)
Current Ratio = 8.32 (Total Current Assets 728.3m / Total Current Liabilities 87.5m)
Debt / Equity = 0.09 (Debt 85.7m / last Quarter total Stockholder Equity 971.5m)
Debt / EBITDA = -0.31 (Net Debt -250.1m / EBITDA -277.2m)
Debt / FCF = -0.41 (Debt 85.7m / FCF TTM -207.3m)
Total Stockholder Equity = 871.6m (last 4 quarters mean)
RoA = -24.35% (Net Income -275.4m, Total Assets 1.13b )
RoE = -31.60% (Net Income TTM -275.4m / Total Stockholder Equity 871.6m)
RoCE = -30.23% (Ebit -285.3m / (Equity 871.6m + L.T.Debt 72.0m))
RoIC = -32.73% (NOPAT -285.3m / Invested Capital 871.6m)
WACC = 9.28% (E(3.36b)/V(3.45b) * Re(9.51%)) + (D(85.7m)/V(3.45b) * Rd(0.13%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.60%
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -207.3m)
Revenue Correlation: -1.35 | Revenue CAGR: 6.90%
Rev Growth-of-Growth: -34.47
EPS Correlation: -36.00 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -50.73
Additional Sources for KYMR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle